ZIOPHARM Oncology, Inc. ZIOP
Set alert
0.87 0.00 0.00%
At close
0.8611 Day range 0.97
52-week range unavailable
- Open
- 0.89
- Prev close
- 0.8657
- Mkt cap
- 208.12M
- Vol
- 2.13M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.8611
- High
- 0.97
- Forward P/E
- -2.55
- Beta
- 1.69
- Short ratio
- 14.08
- Inst. own
- 56.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 24, 2022
- 50-d avg
- 1.07
- 200-d avg
- 1.89
- 1y target
- 3.92
Analyst view
Consensus: hold
Hold
Price target (mean) 3.92 +352.8% upside
Now 0.8657
- Target (low)
- 1.50
- Target (mean)
- 3.92
- Target (high)
- 7.50
Ratings (0m) 6 2 buy · 4 hold · 0 sell
- Strong buy1
- Buy1
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 7
- 2 months ago 7
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.08 | -0.11 – -0.05 | -0.11 | +27.3% | 0 | 0.0% | 7 |
| Next quarter | -0.08 | -0.10 – -0.06 | -0.10 | +20.0% | 0 | 0.0% | 4 |
| Current year | -0.40 | -0.42 – -0.37 | -0.38 | -5.3% | 340.00K | 0.0% | 7 |
| Next year | -0.34 | -0.45 – -0.16 | -0.40 | +15.0% | 0 | 0.0% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 9, 2021 | Raymond James | Maintained | — | Market Perform |
| Aug 10, 2021 | Raymond James | Downgrade | Outperform | Market Perform |
| May 7, 2021 | Raymond James | Maintained | — | Outperform |
| Mar 12, 2021 | Jefferies | Downgrade | Buy | Hold |
| Mar 1, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jun 19, 2020 | Jefferies | Initiated | — | Buy |
| May 11, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 4, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 3, 2020 | Raymond James | Maintained | — | Outperform |
| Apr 4, 2019 | Lake Street | Initiated | — | Buy |
| Apr 1, 2019 | Laidlaw & Co. | Initiated | — | Buy |
| Nov 15, 2018 | Raymond James | Upgrade | Market Perform | Outperform |
| Jun 18, 2018 | JP Morgan | Downgrade | Neutral | Underweight |
| Jun 1, 2017 | H.C. Wainwright | Initiated | — | Buy |
| Aug 10, 2016 | Wells Fargo | Upgrade | Underperform | Market Perform |
| Jun 2, 2016 | Raymond James | Initiated | — | Market Perform |
| Dec 4, 2015 | Wells Fargo | Initiated | — | Underperform |
| Jun 22, 2015 | BMO Capital | Downgrade | Outperform | Market Perform |
| May 13, 2015 | Guggenheim | Initiated | — | Neutral |
| Mar 10, 2015 | Mizuho | Downgrade | Buy | Neutral |
| Mar 2, 2015 | Mizuho | Maintained | — | — |
| Jan 13, 2015 | BMO Capital | Upgrade | Underperform | Outperform |
| Mar 4, 2014 | PiperJaffray | Upgrade | Underweight | Neutral |
| Mar 27, 2013 | Brinson Patrick | Downgrade | Outperform | Market Perform |
| Mar 26, 2013 | PiperJaffray | Downgrade | Neutral | Underweight |
| Mar 26, 2013 | Jefferies | Maintained | — | Hold |
| Mar 26, 2013 | JP Morgan | Downgrade | Overweight | Neutral |
| Mar 26, 2013 | BMO Capital | Downgrade | Market Perform | Underperform |
| Jan 17, 2013 | PiperJaffray | Initiated | — | Neutral |
| Dec 12, 2012 | Jefferies | Downgrade | Buy | Hold |